Evopoint and Kaken also ring in the new year with multiple deals. Biocytogen licenses antibodies against a specified target derived from its RenMice platform technology to Hansoh Pharma.

With only weeks to go in 2022, the three major pharmas each had inked between 16 and 20 deals. Meanwhile, Pfizer has been less busy with 12 deals, but those include M&A totaling $18.2bn.

Emerging Company Profile: Mini-proteins offer some of the capabilities of small molecules and antibodies with fewer limitations, Ordaõs claims. The biotech wants to lead a paradigm shift from discovery to design.

Building a narrow set of products and services that provide reliable and consistent revenue is a perfectly sound business strategy and one that sustains many biotech companies. But for the hungrier, like Twist Bioscience, Inc., a strategy of ongoing disruption and evolution has been more appealing and indeed is generating significant growth. Emily Leproust, Twist’s CEO, spoke with In Vivo about what it means to follow a value-added business strategy.